Interrupting vaccination policies can greatly spread SARS-CoV-2 and enhance mortality from COVID-19 disease: the AstraZeneca case for France and Italy
Résumé
Several European countries have suspended the inoculation of the AstraZeneca vaccine out of suspicion of causing deep vein thrombosis. In this letter we report some Fermi estimates performed using a stochastic model aimed at making a risk-benefit analysis of the interruption of the delivery of the AstraZeneca vaccine in France and Italy. Our results clearly show that excess deaths due to the interruption of the vaccination campaign injections largely overrun those due to thrombosis even in worst case scenarios of frequency and gravity of the vaccine side effects.
Fichier principal
Faranda_et_al_AstraZeneca.pdf (543.65 Ko)
Télécharger le fichier
Faranda_et_al_AstraZeneca_SM.pdf (386.14 Ko)
Télécharger le fichier
Resume_Faranda_et_al_preprint_Francais.pdf (300.15 Ko)
Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)